Registered title, quoted from ClinicalTrials.gov
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 9 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 9
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
- Study siteChildren's Hospital, Zhejiang University School of Medicine浙江大学医学院附属儿童医院HangzhouHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteInstitute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)TianjinHospital page
- Study siteNanfang Hospital南方医科大学南方医院GuangzhouHospital page
- Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
- Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
- Study siteWest China Second University Hospital四川大学华西第二医院ChengduHospital page
- Study siteXinqiao Hospital, Army Medical University陆军军医大学第二附属医院(新桥医院)ChongqingHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05579132, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 1
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (1 points)Hide the checklist
2 years to Not stated; sex: all
Registered eligibility fields
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05579132, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
The main inclusion criteria include but are not limited to:
- Adult participants must be age 18 or older
- Pediatric participants must be at least 2 years old and less than 18 years old.
- Diagnosis of precursor B-cell acute lymphoblastic leukemia (B-ALL) and have more than 5% blasts in the bone marrow by morphological assessment
- Participants with Ph-negative B-ALL with any of the following refractory/relapse criteria:
- Failure to achieve complete remission after initial induction therapy;
- Failure to achieve complete remission after salvage treatment;
- Relapse with first remission duration ≤12 months
- Second or later relapse
- Relapse after allogeneic HSCT
- Participants with Ph-positive B-ALL who have received 2 (or more) tyrosine kinase inhibitors (TKIs) and meet the refractory/relapse criteria above or, those with the T315I mutation
The main exclusion criteria include but are not limited to:
- History of Burkitt's leukemia.
- Received anti-CD19 therapy within 3 months prior to entering the study
- Received allogeneic HSCT within 12 weeks prior to entering the study
- Received prior treatment with chimeric antigen receptor T cell (CAR-T) within 3 months prior to entering the study
- History or presence of clinically relevant central nervous system (CNS) pathology
- Has CNS infiltration. Participants who had previous CNS infiltration, but it was controlled with intrathecal therapy are permitted to enroll.
- History of immunodeficiency, including history of any positive test result for human immunodeficiency virus (HIV) antibody.
- History of serious cardiovascular and cerebrovascular disease
- Has active autoimmune diseases that may relapse
Quoted from ClinicalTrials.gov, NCT05579132, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05579132, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.